The Vanguard Group, Inc. has recently announced that it has increased stake in Guardion Health Sciences Inc. (NASDAQ:GHSI) by 25.80%. After grabbing 0.69 million shares, the institutional investor is now in possession of 0.14 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.80% having worth around $0.29 million. Moreover, G1 Execution Services LLC increased its share by 0.17 million to have a control over 0.18 million shares. And Virtu Financial BD LLC raised its holdings to 40684.0 shares by acquiring 0.18 million shares or 0.21% of the stake.
Guardion Health Sciences Inc. (GHSI) concluded trading on 08/27/20 at a closing price of $0.33, with 2.62 million shares of worth about $0.87 million changed hands on the day. Weekly performance of the stock remained positive as price took a surge of 13.72% during that period and on Thursday the price saw a loss of about -3.21%. Currently the company’s common shares owned by public are about 78.63M shares, out of which, 78.30M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Guardion Health Sciences Inc. Vanguard Total Stock Market Index is currently holding 1.13 million shares of worth totaling $0.48 million. The company recently came buying 1.13 million shares which brought its stake up to 1.32% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 0.27 million shares, have now control over 0.32% of the stake in the company. It holds 0.0 shares of worth $0.12 million.
Guardion Health Sciences Inc. (NASDAQ: GHSI) started trading at $0.335, below -$0.01 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $0.33, or with a loss of -3.21%. Stock saw a price change of 13.72% in past 5 days and over the past one month there was a price change of -21.77%. Year-to-date (YTD), GHSI shares are showing a performance of 52.01% which increased to 32.32% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.17 but also hit the highest price of $0.95 during that period. While comparing its average daily trading volume of 5.71 million shares, we see that about 2.62 million changed hands on the day. The stock is currently trading -10.98% below its 20-day simple moving average (SMA20), while that difference is down -19.16% for SMA50 and it goes to -10.29% lower than SMA200.
The Vanguard Group, Inc. acquired 0.69 million shares of Guardion Health Sciences Inc. having value of about $0.29 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.14 million shares in the company valued at close to $46596.0, or have control over 25.80% stake in the company. Guardion Health Sciences Inc. (NASDAQ: GHSI) currently have 78.63M outstanding shares and institutions hold larger chunk of about 2.20% of that. Holding of mutual funds in the company is about 2.48% while other institutional holders and individual stake holders have control over 3.51% and -0.17% of the stake respectively.
The stock has a current market capitalization of $26.88M. It has posted earnings per share of -$0.24 in the same period. It has Quick Ratio of 11.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GHSI, volatility over the week remained 11.27% while standing at 8.55% over the month.
Stock’s fiscal year EPS is expected to rise by 22.50%.
Analysts at 0 brokerage firms have issued recommendations for the Guardion Health Sciences Inc. (GHSI)’s stock out of those 0 Wall Street analysts, 0 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.